Naltrexone for Individuals of East Asian Descent

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will elucidate the pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene on biobehavioral and neural markers of response to naltrexone in individuals of East Asian descent, an ethnic group most likely to express the positive predictive allele.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Los Angeles
• Collaborator: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• Treatments: Naltrexone

Criteria

Inclusion Criteria:

• current (i.e., past month) alcohol dependence

• East Asian ethnicity (i.e., Chinese, Korean, or Japanese)

• Prospective genotyping for the A118G SNP of the mu opioid receptor (OPRM1) gene to allow for balanced groups on all three genotypes (AA, AG, GG)

Exclusion Criteria:

• lifetime DSM-IV of drug dependence (other than alcohol or nicotine)

• current use of psychoactive drugs as determined by self-reports and verified using toxicology testing

• lifetime diagnosis of bipolar disorder or any psychotic disorder

• contraindications to an MRI scan (including left handedness)